Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Dynacil
2. Fosenopril
3. Fosinil
4. Fosinopril
5. Fosinopril Sodium
6. Fosinopril, (1(s*(r*)),2 Alpha,4 Alpha)-(d-pro)-isomer
7. Fosinopril, (1(s*(r*)),2 Alpha,4 Beta)-isomer
8. Fosinopril, (1(s*(s*)),2 Alpha,4 Beta)-isomer
9. Fosinorm
10. Fositens
11. Fozitec
12. Hiperlex
13. Monopril
14. Newace
15. Sodium, Fosinopril
16. Sq 28,555
17. Sq 28555
18. Sq-28,555
19. Sq-28555
20. Sq28,555
21. Sq28555
22. Staril
23. Tenso Stop
24. Tensocardil
1. Fosinopril Sodium
2. 88889-14-9
3. Chebi:5164
4. 1217528-56-7
5. Dynacil
6. Eliten
7. Sodium;(2s,4s)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate
8. Sodium (2s,4s)-4-cyclohexyl-1-(2-((2-methyl-1-(propionyloxy)propoxy)(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylate
9. Fosinopril Sodium- Bio-x
10. Ncgc00167432-01
11. Dsstox_cid_26621
12. Dsstox_rid_81772
13. Dsstox_gsid_46621
14. Schembl40690
15. Chembl3188382
16. Dtxsid7046621
17. Tox21_112436
18. Mfcd00897699
19. Akos015888700
20. Ac-6227
21. Bcp9000703
22. Bs-1003
23. Sq28555
24. Bf164489
25. Cas-88889-14-9
26. A842989
27. Sodium (2s,4s)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylate
28. Sodium (2s,4s)-4-cyclohexyl-1-(2-((2-methyl-1-(propionyloxy)propoxy)(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-
29. Sodium (2s,4s)-4-cyclohexyl-1-(2-((2-methyl-1-(propionyloxy)propoxy)-(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylate
30. Sodium (2s,4s)-4-cyclohexyl-1-(2-{[2-methyl-1-(propionyloxy) Propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylate
31. Sodium(2s,4s)-4-cyclohexyl-1-(2-((2-methyl-1-(propionyloxy)propoxy)(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylate
| Molecular Weight | 585.6 g/mol |
|---|---|
| Molecular Formula | C30H45NNaO7P |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 15 |
| Exact Mass | 585.28313405 g/mol |
| Monoisotopic Mass | 585.28313405 g/mol |
| Topological Polar Surface Area | 113 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 857 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Fosinopril sodium |
| Drug Label | Fosinopril sodium tablet, USP is the sodium salt of fosinopril USP, the ester prodrug of an angiotensin converting enzyme (ACE) inhibitor, fosinoprilat. It contains a phosphinate group capable of specific binding to the active site of angiotensin con... |
| Active Ingredient | Fosinopril sodium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 10mg; 40mg; 20mg |
| Market Status | Prescription |
| Company | Actavis Labs Fl; Teva; Apotex; Aurobindo Pharma; Sandoz; Invagen Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Fosinopril sodium |
| Drug Label | Fosinopril sodium tablet, USP is the sodium salt of fosinopril USP, the ester prodrug of an angiotensin converting enzyme (ACE) inhibitor, fosinoprilat. It contains a phosphinate group capable of specific binding to the active site of angiotensin con... |
| Active Ingredient | Fosinopril sodium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 10mg; 40mg; 20mg |
| Market Status | Prescription |
| Company | Actavis Labs Fl; Teva; Apotex; Aurobindo Pharma; Sandoz; Invagen Pharms |
Angiotensin-Converting Enzyme Inhibitors
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
29
PharmaCompass offers a list of Fosinopril API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Fosinopril manufacturer or Fosinopril supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fosinopril manufacturer or Fosinopril supplier.
A Sapril manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sapril, including repackagers and relabelers. The FDA regulates Sapril manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sapril API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sapril manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Sapril supplier is an individual or a company that provides Sapril active pharmaceutical ingredient (API) or Sapril finished formulations upon request. The Sapril suppliers may include Sapril API manufacturers, exporters, distributors and traders.
click here to find a list of Sapril suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Sapril DMF (Drug Master File) is a document detailing the whole manufacturing process of Sapril active pharmaceutical ingredient (API) in detail. Different forms of Sapril DMFs exist exist since differing nations have different regulations, such as Sapril USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sapril DMF submitted to regulatory agencies in the US is known as a USDMF. Sapril USDMF includes data on Sapril's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sapril USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sapril suppliers with USDMF on PharmaCompass.
A Sapril CEP of the European Pharmacopoeia monograph is often referred to as a Sapril Certificate of Suitability (COS). The purpose of a Sapril CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Sapril EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Sapril to their clients by showing that a Sapril CEP has been issued for it. The manufacturer submits a Sapril CEP (COS) as part of the market authorization procedure, and it takes on the role of a Sapril CEP holder for the record. Additionally, the data presented in the Sapril CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Sapril DMF.
A Sapril CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Sapril CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Sapril suppliers with CEP (COS) on PharmaCompass.
A Sapril written confirmation (Sapril WC) is an official document issued by a regulatory agency to a Sapril manufacturer, verifying that the manufacturing facility of a Sapril active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sapril APIs or Sapril finished pharmaceutical products to another nation, regulatory agencies frequently require a Sapril WC (written confirmation) as part of the regulatory process.
click here to find a list of Sapril suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sapril as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sapril API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sapril as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sapril and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sapril NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sapril suppliers with NDC on PharmaCompass.
Sapril Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sapril GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Sapril GMP manufacturer or Sapril GMP API supplier for your needs.
A Sapril CoA (Certificate of Analysis) is a formal document that attests to Sapril's compliance with Sapril specifications and serves as a tool for batch-level quality control.
Sapril CoA mostly includes findings from lab analyses of a specific batch. For each Sapril CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sapril may be tested according to a variety of international standards, such as European Pharmacopoeia (Sapril EP), Sapril JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sapril USP).